Fewer than a tenth of individuals who could benefit from weight-loss injections such as Wegovy are able to get them, states the World Health Organization as it issues its initial recommendations on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is calling for broader and more equitable availability to these injectable treatments.
Based on projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"Our new guidance acknowledges that obesity is a lifelong illness that can be managed with thorough and lifelong support," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key hurdles to universal availability to the treatments that can assist patients in reducing significant body mass, explains the organization.
Skinny Jab Supply Crisis
Despite the current most favorable outlook, the production of GLP-1 therapies might only reach around 100 million people – less than 10% of the global need, according to the WHO.
The guideline urges countries and companies to increase availability, through strategies like voluntary licensing.
Exclusive production rights on semaglutide – the core ingredient of a leading brand – is set to lapse in multiple nations in 2026.
How Weight-Loss Drugs Function
These medications mimick a body's own hormone to reduce digestion speed, reduce hunger and enhance the sense of being full so people eat less.
Patients usually begin shedding pounds after several weeks of beginning the weekly injections.
Studies points to users may put most of the weight back on a year later of halting the treatment, because their usual food cravings come back.
Being overweight or obese increases your likelihood for developing diseases, such as diabetes, heart disease, brain attack, and certain cancers.
Excess weight impacts people in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, as per the WHO.
